Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Nanoparticle Improves Leishamiasis Drug Efficacy by 83%

By Drug Discovery Trends Editor | November 5, 2013

Researchers have developed a method which allows to drastically reduce the drug dose of amphotericin B, as it improves its efficacy 83%, multiplies by 10 the capacity of the drug to attack cell infected by the parasite that provokes the disease and significantly reduces the toxicity of the parasite. (Source: CDC)The amphotericin B (AmB) is the main active ingredient in the most effective drug used to treat leishmaniasis, a disease that affects over 12 million people in developing countries, with more than 70,000 deaths per year. The cost of treating humans with AmB surpasses $5,000 per patient, the treatment is extensive (2-hour sessions every day during 21 days) and the side effects are frequent and many times patients must be hospitalised.
 
Researchers from the University of Miami, Florida and the Universitat Autònoma de Barcelona have developed a method which allows to drastically reduce the drug dose, as it improves its efficacy 83%, multiplies by 10 the capacity of the drug to attack cell infected by the parasite that provokes the disease and significantly reduces the toxicity of the parasite. In a paper published in The Journal of Infectious Diseases, the researchers report that the method has been successfully tested on mice models of leishmaniasis.
 
The complex compound acts through the action of a pan-DR-binding epitope derivatized-dendrimer (PDD) nanoparticle, a substance that measures 10 nanometres in diameter and fits into the active principle, amphotericin B, guiding it to the cells that harbor the parasite. 
 
While the usual complete dose of the drug requires over 12 days to reduce the skin lesions caused by the disease, scientists observed that one dose of the complex compound with only 17% of the complete dose of the drug improves skin lesions in two or three days in the study. Moreover, the complex compound acts as a therapeutic vaccine which activates the immune system against the reservoir cells hosting the parasite.
 
The PDD substance has been used in previous trials with people with the aim of improving the response of their immune system to other diseases. Now there is a need for clinical trials with humans in order to verify its safety as an adjuvant in the treatment of leishmaniasis. If its safety in humans is confirmed, it will also reduce the cost of the treatment drastically, and this is a key element in reducing mortality rates in developing countries.
 
 
Date: November 5, 2013
Source: Universitat Autonoma de Barcelona

Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE